<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02271516</url>
  </required_header>
  <id_info>
    <org_study_id>QCR12009</org_study_id>
    <nct_id>NCT02271516</nct_id>
  </id_info>
  <brief_title>to evaluate188Re-BMEDA-liposome in Patient With Primary Solid Tumor in Advanced or Metastatic Stage</brief_title>
  <official_title>A Phase I, Open-label, Dose-escalation Study to Determine the Maximum Tolerance Dose (MTD) and to Evaluate the Safety of 188Re-BMEDA-liposome in Patient With Primary Solid Tumor in Advanced or Metastatic Stage.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Nuclear Energy Research, Taiwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Nuclear Energy Research, Taiwan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to determine the maximum tolerance dose (MTD) and to evaluate the safety of&#xD;
      188Re-BMEDA-liposome in patient with primary solid tumor in advanced or metastatic stage.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rhenium-188 is an ideal radionuclide for therapeutic use due to its maximum beta emission of&#xD;
      2.12MeV, short physical half-life of 16.9 hours, and its 155-keV gamma emission for imaging&#xD;
      purposes. 188Re-BMEDA-liposome consists of 2 separate components (Rhenium-188 and liposome)&#xD;
      and BMEDA as a linker. This study aims to find the MTD, evaluate the safety, efficacy&#xD;
      profiles and investigate the biodistribution, radioactivity and radiation dosimetry of&#xD;
      188Re-BMEDA-liposome on primary solid tumor in metastatic stage patient by a single&#xD;
      intravenous injection course.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Some concerns arose for the accumulation of radioactivity in liver and spleen.&#xD;
  </why_stopped>
  <start_date type="Actual">October 2014</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the MTD</measure>
    <time_frame>up to 30 days per cohort</time_frame>
    <description>The design will use cohort of 3 patients. If none of the first 3 patients experience DLT, then dose escalation will proceed for the next dose level of patients unless the present dose level is level 6 (1.47±0.15 mCi/kg).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in vital signs and pysical examination</measure>
    <time_frame>from day 0 to up t0 60 days per cohort</time_frame>
    <description>assess the safety issue from the change in vital signs (BP, PR, RR and temperature) and physical examinations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in lab data</measure>
    <time_frame>from day 0 to up t0 60 days per cohort</time_frame>
    <description>assess the safety issue from the change in lab data including heatology lab data change, Biochemistry laboratory data change and urinalysis data change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event(s)</measure>
    <time_frame>from day 0 to up t0 60 days per cohort</time_frame>
    <description>assessed by NCI CTCAE (National Cancer Institute Common Terminology Criteria for Adverse Events) v4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse event(s)</measure>
    <time_frame>from day 0 to up t0 60 days per cohort</time_frame>
    <description>All AE(s) and SAE(s) which occurred within follow-up visit after the single dose administration of study drug should be followed until resolution or the event is considered stable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in EKG</measure>
    <time_frame>in 24hrs</time_frame>
    <description>Patient will be examined the EKG by standard 12-lead at screen visit for eligibility. After enrollment, patient will be attached on a 24h-portable EKG monitor to monitoring EKG before and post-administration of Stage I and II low dose and therapeutic infusion dose for 24hrs</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Tumors</condition>
  <arm_group>
    <arm_group_label>188Re-BMEDA-liposome</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stage I:&#xD;
188Re-BMEDA-liposomes, 14±1.4 mCi, single dose&#xD;
Stage II:&#xD;
188Re-BMEDA-liposomes, dose-escalation, single dose Dose Level Dose of 188Re-BMEDA-liposome (mCi/kg)&#xD;
0.42±0.04 mCi/kg&#xD;
0.63±0.06 mCi/kg&#xD;
0.84±0.08 mCi/kg&#xD;
1.05±0.11 mCi/kg&#xD;
1.26±0.13 mCi/kg&#xD;
1.47±0.15 mCi/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>188Re-BMEDA-liposome</intervention_name>
    <description>EKG at baseline and in 24hours after administration</description>
    <arm_group_label>188Re-BMEDA-liposome</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with histologically confirmed diagnosis of primary solid tumor, and with&#xD;
             pathologically or radiologically documented metastases&#xD;
&#xD;
          -  Disease that is measurable or evaluable by RECIST 1.1 criteria (for Solid Tumors)&#xD;
&#xD;
          -  Patient with metastatic cancer that are refractory to current standard/available&#xD;
             therapies&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  brain metastases&#xD;
&#xD;
          -  serious concurrent infection or nonmalignant illness that is uncontrolled&#xD;
&#xD;
          -  uncontrolled intercurrent illness&#xD;
&#xD;
          -  Immunocompromised&#xD;
&#xD;
          -  significant traumatic injury within 3 weeks before Day 0&#xD;
&#xD;
          -  History of hypersensitivity to any component of study drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shyh-Jen Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taipei Veterans General Hospital (Taiwain)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital (Taiwain)</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 15, 2014</study_first_submitted>
  <study_first_submitted_qc>October 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2014</study_first_posted>
  <last_update_submitted>July 28, 2020</last_update_submitted>
  <last_update_submitted_qc>July 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

